Abstract GS3-09: Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with estrogen receptor-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: City Of Hope National Medical Center, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Universidad Complutense de Madrid, Centro de Investigación Biomédica en Red de Cáncer, GEICAM – Spanish Breast Cancer Group, West Cancer Center, Azienda Ospedaliero-Universitaria di Modena, UPMC Hillman Cancer Center, Northwestern University, German Cancer Research Center, Heidelberg University, Tokai University, Virginia Cancer Specialists, National Cancer Center, Nottingham University Hospitals NHS Trust, Instacart (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129579980